Last reviewed · How we verify

NCT05609552

Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET

Completed Last updated 12 December 2025
What this trial tests

trial testing 18F-Pretomanid PET/CT in Tuberculosis in 10 participants. Completed in 28 October 2025.

Timeline
22 May 2023
Primary endpoint
28 October 2025
28 October 2025

Quick facts

Lead sponsorJohns Hopkins University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment10
Start date22 May 2023
Primary completion28 October 2025
Estimated completion28 October 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Johns Hopkins University

Who can join

18 and older, any sex, with Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational study that will examine the pretomanid pharmacokinetics (PK) in tuberculosis (TB) patients. Dynamic 18F-pretomanid PET/CT will be performed after intravenous injection of 18F-pretomanid to determine multi-compartment, noninvasive determination of pretomanid PK in TB patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs.
    Chen X, Arun B, Nino-Meza OJ, Sarhan MO, et al · · 2024 · cited 13× · PMID 39143055 · DOI 10.1038/s41467-024-50989-4

Verify or expand the search:

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

Other Johns Hopkins University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05609552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing